Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NCCAM St. John’s Wort Studies On OCD, Social Phobia Recruiting Subjects

This article was originally published in The Tan Sheet

Executive Summary

An NCCAM-funded study on the use of St. John's wort to treat obsessive-compulsive disorder is part of an ongoing effort by researchers to find the most appropriate therapeutic applications for the botanical, Duke University's Jonathan Davidson, MD, said at the NIH center's advisory council meeting May 28

You may also be interested in...



Inconclusive St. John’s Wort Trial Prompts Queries On Study Design, Setting

The inconclusive nature of a recent study on St. John's wort suggests the current procedure for funding and designing clinical trials of botanicals may need to be reexamined, according to a letter in the July 24 Journal of the American Medical Association

Inconclusive St. John’s Wort Trial Prompts Queries On Study Design, Setting

The inconclusive nature of a recent study on St. John's wort suggests the current procedure for funding and designing clinical trials of botanicals may need to be reexamined, according to a letter in the July 24 Journal of the American Medical Association

Inconclusive St. John’s Wort Trial Prompts Queries On Study Design, Setting

The inconclusive nature of a recent study on St. John's wort suggests the current procedure for funding and designing clinical trials of botanicals may need to be reexamined, according to a letter in the July 24 Journal of the American Medical Association

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel